FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570366246> ?p ?o ?g. }

• W2570366246 abstract "Abstract Introduction Effective reduction of myeloma before autologous stem cell transplantation (ASCT) prolongs survival in multiple myeloma patients. Recently, incorporation of novel agents resulted in improved response rate and reduced side effect in newly diagnosed multiple myeloma. Method: Patients are planned to receive 2 cycles of VAD (vincristine 0.4mg D1-4, adriamycin 9mg/m2 D1-4, dexamethasone 40mg D1-4, 9–12 every 3 weeks), and VTD (bortezomib 1.3mg/m2 D1, 4, 8, 11, thalidomide 100mg daily, dexamethasone 40mg D1-4, 9–12 every 3 weeks). High dose melphalan (200mg/m2) is used as a conditioning regimen for ASCT. Bortezomib (1.3mg/m2) as a maintenance treatment is administered weekly x 4 times every 6 weeks for 4 cycles after ASCT. Response was assessed by EBMT criteria, with additional category of nCR. Adverse events were graded by the NCI-CTCAE, Version 3.0. Result: At this interim analysis, 60 patients have been entered into the ongoing trial, and efficacy could be assessed in 53 patients. After 2 cycles of VAD, response rate was 70%. After VTD, two patients showed further improvement with additional CR, and an overall response was 97% with 14% CR. Especially, patients with poor prognostic cytogenetics (n=6) all responded after VTD. So far, autologous stem cells were successfully collected in all 28 patients with a median CD34+ count of 7.8 x 106/kg (range, 2.17–44.7 x 106/kg). In 24 patients who underwent autologous stem cell transplantation, five patients gained additional CR. There was no progression in patients completed bortezomib maintenance (n=9, CR 77%). The median follow-up duration was 6 months, median time to response was 1.4 months, and median overall survival was not reached. Grade 3,4 hematologic toxicity was more frequently observed after VAD than VTD (anemia 15.8%, 4.6%, neutropenia 7.9%, 3.5%), and incidence of grade 2,3 peripheral neuropathy was low (VAD 3.5%, VTD 7%). Conclusion: Sequential VAD and VTD induction therapy in newly diagnosed multiple myeloma was highly effective, even in patients with poor prognostic cytogenetics, and did not prejudice stem cell collection. VTD could have contributed to increased RR and minimized side effects. An updated results will be presented at the ASH meeting. *Protocol Number: KMM51-NCT00378755." @default.
• W2570366246 created "2017-01-13" @default.
• W2570366246 creator A5014636746 @default.
• W2570366246 creator A5022259689 @default.
• W2570366246 creator A5024508698 @default.
• W2570366246 creator A5027919726 @default.
• W2570366246 creator A5041004365 @default.
• W2570366246 creator A5043460941 @default.
• W2570366246 creator A5044268319 @default.
• W2570366246 creator A5044958787 @default.
• W2570366246 creator A5055747094 @default.
• W2570366246 creator A5065836913 @default.
• W2570366246 creator A5066039159 @default.
• W2570366246 creator A5068318933 @default.
• W2570366246 creator A5073284312 @default.
• W2570366246 creator A5077318648 @default.
• W2570366246 creator A5086276130 @default.
• W2570366246 creator A5089774294 @default.
• W2570366246 date "2007-11-16" @default.
• W2570366246 modified "2023-10-18" @default.
• W2570366246 title "Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE®, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial." @default.
• W2570366246 doi "https://doi.org/10.1182/blood.v110.11.952.952" @default.
• W2570366246 hasPublicationYear "2007" @default.
• W2570366246 type Work @default.
• W2570366246 sameAs 2570366246 @default.
• W2570366246 citedByCount "3" @default.
• W2570366246 crossrefType "journal-article" @default.
• W2570366246 hasAuthorship W2570366246A5014636746 @default.
• W2570366246 hasAuthorship W2570366246A5022259689 @default.
• W2570366246 hasAuthorship W2570366246A5024508698 @default.
• W2570366246 hasAuthorship W2570366246A5027919726 @default.
• W2570366246 hasAuthorship W2570366246A5041004365 @default.
• W2570366246 hasAuthorship W2570366246A5043460941 @default.
• W2570366246 hasAuthorship W2570366246A5044268319 @default.
• W2570366246 hasAuthorship W2570366246A5044958787 @default.
• W2570366246 hasAuthorship W2570366246A5055747094 @default.
• W2570366246 hasAuthorship W2570366246A5065836913 @default.
• W2570366246 hasAuthorship W2570366246A5066039159 @default.
• W2570366246 hasAuthorship W2570366246A5068318933 @default.
• W2570366246 hasAuthorship W2570366246A5073284312 @default.
• W2570366246 hasAuthorship W2570366246A5077318648 @default.
• W2570366246 hasAuthorship W2570366246A5086276130 @default.
• W2570366246 hasAuthorship W2570366246A5089774294 @default.
• W2570366246 hasConcept C126322002 @default.
• W2570366246 hasConcept C141071460 @default.
• W2570366246 hasConcept C143998085 @default.
• W2570366246 hasConcept C197934379 @default.
• W2570366246 hasConcept C2776063141 @default.
• W2570366246 hasConcept C2776364478 @default.
• W2570366246 hasConcept C2776694085 @default.
• W2570366246 hasConcept C2776755627 @default.
• W2570366246 hasConcept C2777478702 @default.
• W2570366246 hasConcept C2778684742 @default.
• W2570366246 hasConcept C2779050716 @default.
• W2570366246 hasConcept C2779429289 @default.
• W2570366246 hasConcept C2779609412 @default.
• W2570366246 hasConcept C2780401358 @default.
• W2570366246 hasConcept C2781413609 @default.
• W2570366246 hasConcept C2911091166 @default.
• W2570366246 hasConcept C535046627 @default.
• W2570366246 hasConcept C61943457 @default.
• W2570366246 hasConcept C71924100 @default.
• W2570366246 hasConcept C90924648 @default.
• W2570366246 hasConceptScore W2570366246C126322002 @default.
• W2570366246 hasConceptScore W2570366246C141071460 @default.
• W2570366246 hasConceptScore W2570366246C143998085 @default.
• W2570366246 hasConceptScore W2570366246C197934379 @default.
• W2570366246 hasConceptScore W2570366246C2776063141 @default.
• W2570366246 hasConceptScore W2570366246C2776364478 @default.
• W2570366246 hasConceptScore W2570366246C2776694085 @default.
• W2570366246 hasConceptScore W2570366246C2776755627 @default.
• W2570366246 hasConceptScore W2570366246C2777478702 @default.
• W2570366246 hasConceptScore W2570366246C2778684742 @default.
• W2570366246 hasConceptScore W2570366246C2779050716 @default.
• W2570366246 hasConceptScore W2570366246C2779429289 @default.
• W2570366246 hasConceptScore W2570366246C2779609412 @default.
• W2570366246 hasConceptScore W2570366246C2780401358 @default.
• W2570366246 hasConceptScore W2570366246C2781413609 @default.
• W2570366246 hasConceptScore W2570366246C2911091166 @default.
• W2570366246 hasConceptScore W2570366246C535046627 @default.
• W2570366246 hasConceptScore W2570366246C61943457 @default.
• W2570366246 hasConceptScore W2570366246C71924100 @default.
• W2570366246 hasConceptScore W2570366246C90924648 @default.
• W2570366246 hasLocation W25703662461 @default.
• W2570366246 hasOpenAccess W2570366246 @default.
• W2570366246 hasPrimaryLocation W25703662461 @default.
• W2570366246 hasRelatedWork W1913878759 @default.
• W2570366246 hasRelatedWork W2025081120 @default.
• W2570366246 hasRelatedWork W2038371375 @default.
• W2570366246 hasRelatedWork W2106101491 @default.
• W2570366246 hasRelatedWork W2116536558 @default.
• W2570366246 hasRelatedWork W2154021003 @default.
• W2570366246 hasRelatedWork W2559593973 @default.
• W2570366246 hasRelatedWork W2567755155 @default.
• W2570366246 hasRelatedWork W2570366246 @default.
• W2570366246 hasRelatedWork W2981054797 @default.
• W2570366246 isParatext "false" @default.
• W2570366246 isRetracted "false" @default.
• W2570366246 magId "2570366246" @default.
• W2570366246 workType "article" @default.